Clinical Trials Logo

Idiopathic Pulmonary Fibrosis clinical trials

View clinical trials related to Idiopathic Pulmonary Fibrosis.

Filter by:

NCT ID: NCT03120481 Recruiting - Asthma Clinical Trials

Controls for Respiratory Diseases

Start date: April 10, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This is the registry of control participants for patients with various respiratory diseases. We screened healthy volunteers who visited Seoul National Hospital Healthcare System Gangnam Center for routine health check-up, and enrolled patients who agree to participate in the study. The participants undergo baseline questionnaires, provide blood specimen and information of the results of health check-up. We will include participants as controls if they have no significant respiratory symptom and no significant radiographic abnormality. The data from this registry will be compared with those from other registry of various respiratory diseases

NCT ID: NCT03115619 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

PNEUMON
Start date: March 29, 2017
Phase: N/A
Study type: Observational

This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

NCT ID: NCT03104322 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis

Start date: April 2017
Phase: N/A
Study type: Interventional

Pilot-scale, open-label, randomised, two-period crossover study in idiopathic pulmonary fibrosis (IPF) over 16 weeks. Patients will use an electronic health journal (patientMpower platform) to record treatment compliance, forced vital capacity (FVC; daily), impact of IPF on daily life (weekly) and other symptoms. Objectives are to characterise acceptability of patientMpower platform from patient & healthcare professional perspective, impact of active engagement and self-monitoring using patientMpower platform on Patient Reported Outcome Measures (PROMs) in IPF, impact of patientMpower platform on medication compliance and correlation between patient-reported PROMs & FVC and clinical outcomes.

NCT ID: NCT03092102 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

Start date: May 15, 2017
Phase: Phase 1
Study type: Interventional

The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects

NCT ID: NCT03078426 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Lung MRI in the Management of Idiopathic Pulmonary Fibrosis

PIC'IRM
Start date: February 16, 2017
Phase: N/A
Study type: Interventional

High resolution computed tomography (HRCT) plays a major role in the management of idiopathic pulmonary fibrosis (IPF) by identifying characteristic lesions of usual interstitial pneumonia (UIP). Though HRCT is the standard reference to describe pulmonary structural alterations using a non invasive technique, it is nonetheless a radiating exam which provides limited functional information regarding inflammation. In this trial, the investigators aimed to evaluate whether MRI (Magnetic Resonance Imaging) using ultra-short echotime could be an alternative to HRCT in the assessment of the four morphological criteria required to define an UIP pattern. The investigators also planned to study the clinical value of the additional informations derived from MRI such as contrasts and lung perfusion using functional MRI.

NCT ID: NCT03074149 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)

INDULGEIPF
Start date: April 4, 2017
Phase: N/A
Study type: Observational

To gain further insight on the characteristics, management, disease progression and the outcomes of patients with IPF, as diagnosed and treated under real-world, clinical practice conditions in Greece. More specifically, this registry will be used to: Provide a comprehensive clinical picture of IPF, Track access to health care and cost of caring for IPF patients over time, Examine the implementation of treatment guidelines used on patients diagnosed with IPF, according to the existing diagnosis guidelines, Characterization of patients on different treatments. To provide information regarding survival and mortality causes, IPF exacerbations as well as IPF patient co-morbidities including myocardial infarction, CNS infarction, other arterial thromboembolic events, deep vein thrombosis, hemorrhage, gastrointestinal perforation and pulmonary hypertension. Data regarding IPF patient hospitalization will be collected and evaluated with regards to potential respiratory causes, and there will be documentation of treatment patterns and economic aspects. Patients will be followed up for 2 years and information regarding IPF treatment changes since the last visit will be collected.

NCT ID: NCT03069989 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging

Start date: April 21, 2017
Phase: Phase 1
Study type: Interventional

GSK3008348 is being developed as a treatment for IPF. A first-time-in-human study showed that single nebulized doses of 1−3000 micrograms (mcg) GSK3008348 in healthy volunteers were well tolerated, with pharmacokinetic (PK) exposures within the defined limits set in the protocol. The proposed study is a 2-cohort study of single doses, intended to evaluate the safety, tolerability and PK of the drug in participants with IPF not currently treated with pirfenidone or nintedanib, and to obtain preliminary information on target engagement. Cohort 1 will be a 2-period, randomized, double-blind, placebo-controlled group with at least 7 days washout between doses, and follow-up period of up to 7-14 days. Cohort 2 is optional. It will be designed to further explore safety and to provide additional information on the target engagement profile of GSK3008348. The total duration of the study will be up to 62 days.

NCT ID: NCT03050255 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis (IPF)

Short-term Effects of Supplemental Oxygen in Patients With IPF

IPFO2
Start date: November 2016
Phase: N/A
Study type: Interventional

Although exercise-induced desaturation is frequently observed in patients with idiopathic pulmonary fibrosis (IPF) short-term effects of supplemental oxygen during walking have not been investigated yet. Given, that walking ability is the most important activity of daily life, the aim of our study is to investigate the effects of supplemental oxygen on endurance walking capacity in hypoxemic IPF patients. In this study patients will perform 3 endurance shuttle walk tests (ESWTs) at 85% of their individual peak performance using medical air (=compressed room air, 2 liters/minute), 2 liters/minute oxygen, 4 liters/minute Oxygen in a double-blinded fashion and random order. Since there are only limited pharmacological treatment options for IPF patients, this study may help to provide novel information about the short-term effects of supplemental oxygen. Furthermore it may help to investigate possibilities to optimize oxygen therapy in order to facilitate patients´ participation in activities of daily life and not at least to improve patients´ quality of life.

NCT ID: NCT03047031 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis

Start date: April 6, 2017
Phase: N/A
Study type: Observational

This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis. The safety of nintedanib has been assessed in clinical trials. Since only 20 patients from India were enrolled in the INPULSIS trials, the safety data on Indian patients is limited. In this active surveillance, the safety of nintedanib in IPF patients will be examined in Indian real world setting

NCT ID: NCT03041623 Recruiting - Clinical trials for Idiopathic Interstitial Pneumonia

Japanese Idiopathic Interstitial Pneumonias Registry

JIPS
Start date: December 2016
Phase: N/A
Study type: Observational [Patient Registry]

An objective of JIPS Registry is to examine disease prevalence of idiopathic interstitial pneumonias (IIPs), considering classification, background, and diagnostic methods based on American Thoracic Society (ATS)/ European Respiratory Society(ERS) /Japanese Respiratory Society (JRS)/ Latin American Thoracic Association (ALAT) guidelines for diagnosis and the ATS/ERS classification of 2002 and 2013.